2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients
2001
NSAIDs and the Kidney Revisited: Are Selective Cyclooxygenase-2 Inhibitors Safe?
Eras J, Perazella M. NSAIDs and the Kidney Revisited: Are Selective Cyclooxygenase-2 Inhibitors Safe? The American Journal Of The Medical Sciences 2001, 321: 181-190. PMID: 11269794, DOI: 10.1097/00000441-200103000-00005.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsCOX-2 selective inhibitorsSelective cyclooxygenase-2 inhibitorRenal effectsCyclooxygenase-2 inhibitorNonselective nonsteroidal anti-inflammatory drugsSelective nonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsAdverse renal effectsBaseline patient characteristicsAdverse gastrointestinal effectsCOX-1/COXCyclooxygenase enzyme activityAnti-inflammatory drugsCOX-2 inhibitorsCOX-2 enzymePatient characteristicsGastrointestinal effectsChronic painGastric erosionsInflammatory conditionsClinical studiesClinical investigationKidney tissueKidney